This clinical trial is focused on studying Crohn’s Disease, a condition that causes inflammation in the digestive tract, leading to symptoms like abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The study is testing a medication called Ozanimod, which is taken orally in the form of hard capsules. The purpose of the study is to evaluate how effective and safe Ozanimod is for children and teenagers who have moderate to severe Crohn’s Disease and have not responded well to standard treatments.

Participants in the study will be randomly assigned to receive either Ozanimod or a placebo. The study will last for a period of time, during which participants will take the medication daily. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the medication. The goal is to see if Ozanimod can help achieve clinical remission, which means reducing the symptoms of the disease, and endoscopic remission, which means healing the lining of the intestine, by the end of the study period.

This study is important because it aims to find a new treatment option for young people with Crohn’s Disease who have not had success with other therapies. By participating, researchers hope to gather valuable information that could lead to better management of the disease in the future. The study will also look at how the body processes Ozanimod and how it affects the immune system, which plays a role in Crohn’s Disease.